Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
Holding ALEC?
Track your performance easily
ALEC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $7.58
Previous CloseN/A
Volume194.31K
Average Volume (3M)1.46M
Market Cap
$164.53M
Enterprise Value$31.88M
Total Cash (Recent Filing)$50.84M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Apr 01, 2025EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding97,932,600
10 Day Avg. Volume824,660
30 Day Avg. Volume1,463,119
Standard Deviation0.20
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.67
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit0.33
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$4.93Price Target Upside188.30% Upside
Rating ConsensusHold
Number of Analyst Covering8
Alector News
Bulls Say, Bears Say
Bulls Say
Clinical Research And DevelopmentThe PGRN program, specifically AL001, has shown the ability to increase PGRN levels in the brain and slow disease progression, offering promising results for future studies.
Financial PerformanceALEC finds itself in an enviable position of having a reaffirmed cash runway through 2026, enough to get it through its next major potential catalyst.
Strategic CollaborationsAlector is focusing on five early-stage programs based on their ABC transport technology, which could open potential collaboration opportunities and increase valuation.
Bears Say
Clinical Trial ResultsThe Phase 2 INVOKE-2 trial for the AL002 antibody in Alzheimer's disease patients did not achieve its primary endpoint, marking the end of the AL002 program.
Stock And Analyst SentimentALEC shares fell as much as 35-40% in post-market trading due to the disappointing AL002 results.
Workforce And Financial ImpactAlector announced a 17% workforce reduction and the discontinuation of the current AL002 long-term extension study due to the negative data outcome.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $1.60 and its highest was $7.58 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $164.53M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Apr 01, 2025 which is in 73 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Nov 06, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.534 by $0.104.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.63.
How many shares outstanding does Alector Inc have?
Alector Inc has 97,932,600 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.534. Following the earnings report the stock price went up 7.634%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
---
Alector Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.93 (188.30% Upside)
$4.93 (188.30% Upside)
Blogger Sentiment
Bullish
ALEC Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 83.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $276.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.97%
12-Months-Change
Fundamentals
Return on Equity
-112.55%
Trailing 12-Months
Asset Growth
-23.26%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
---
ALEC Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial health and advancements in clinical programs, particularly with AL002 and latozinemab. However, challenges such as MRI abnormalities in trials and uncertain regulatory pathways present potential hurdles.Read More>---
ALEC Stock 12 Month Forecast
Average Price Target
$4.93
▲(188.30% Upside)
Technical Analysis
Alnylam Pharma
―
Denali Therapeutics
―
Fate Therapeutics
―
SAGE Therapeutics
―
Sangamo Biosciences
―
Voyager Therapeutics
―
Best Analysts Covering ALEC
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-17.96%
reiterated a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -17.96% per trade.
---